Tag: Cyramza

May 13, 2019 Off

Lilly gets fifth FDA approval for Cyramza

By Dino Mustafić

Eli Lilly’s Cyramza got its fifth FDA approval for in an advanced or metastatic cancer – this one for the second-line treatment of patients with hepatocellular carcinoma (HCC) who are AFP-High (AFP ≥400 ng/mL).

September 28, 2015 Off

Cyramza Phase II study meets its primary endpoint

By Dino Mustafić

Phase II study of its Cyramza (ramucirumab) in combination with docetaxel met its primary endpoint, demonstrating a statistically significant increase in progression-free survival (PFS) for patients with locally advanced or metastatic urothelial carcinoma who failed prior platinum-based therapy.